Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer

Recruiting now · Not applicable

Conditions studied: Diabetes, IPMN, Pancreatic, PDAC - Pancreatic Ductal Adenocarcinoma

In brief

LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.

Key facts

Study ID

NCT07659639

Run by

Fondazione Policlinico Universitario Campus Bio-Medico

People needed

400

Starts

2025-09-01

Expected to finish

2029-08-01

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Severe pre-existing medical conditions, such as serious illnesses or other medical conditions that could negatively affect study outcomes or pose a high risk to the patient's health;
• Ongoing therapies that could interfere with the study or alter the results.

Where it is running

• Fondazione Policlinico Universitario Campus Bio-Medico — Rome, Italy, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.